Table 8.
COVID-19 outcomes in subgroup (rituximab vs. tumor necrosis factor inhibitors) in RA with COVID-19 cohort before and after propensity matching (COVID-19 diagnosis anytime between January 20, 2020 and April 11, 2021).
| Outcome | Before Propensity Matching | After Propensity Matching | ||||||
|---|---|---|---|---|---|---|---|---|
| RA with COVID-19 with Rituximab (n = 202) | RA with COVID-19 with TNFi† (n = 937) | Risk ratio (95% CI) |
P value | RA with COVID-19 with Rituximab (n = 198) | RA with COVID-19 with TNFi† (n = 198) |
Risk ratio (95% CI) |
P value | |
| Mortality | < 11¶ | 21 (2.2%) |
NA | NA | < 11¶ | < 11¶ | NA | NA |
| Hospitalization | 65 (32.2%) |
150 (16.0%) |
2.01 (1.57, 2.58) |
< 0.0001 | 64 (32.3%) |
36 (18.2%) |
1.78 (1.24, 2.54) |
0.0012 |
| ICU admission | 18 (8.9%) |
30 (3.2%) |
2.78 (1.58, 4.89) |
0.0002 | 18 (9.1%) |
< 11¶ | NA | NA |
| Mechanical ventilation | < 11¶ | 19 (2.0%) |
NA | NA | < 11¶ | < 11¶ | NA | NA |
| Severe COVID-19§ | < 11¶ | 31 (3.3%) |
NA | NA | < 11¶ | < 11¶ | NA | NA |
| Acute kidney injury | 20 (9.9%) |
50 (5.3%) |
1.86 (1.13, 3.05) |
0.0143 | 19 (9.6%) |
15 (7.6%) |
1.27 (0.66, 2.42) |
0.4731 |
| KRT/Hemodialysis | < 11¶ | < 11¶ | NA | NA | < 11¶ | < 11¶ | NA | NA |
| ARDS | < 11¶ | 12 (1.3%) |
NA | NA | < 11¶ | < 11¶ | NA | NA |
| Ischemic Stroke | < 11¶ | < 11¶ | NA | NA | < 11¶ | < 11¶ | NA | NA |
| VTE | 17 (8.4%) |
21 (2.2%) |
3.76 (2.02, 6.99) |
< 0.0001 | 17 (8.6%) |
< 11¶ | NA | NA |
| Sepsis | 18 (8.9%) |
34 (3.6%) |
2.46 (1.42, 4.26) |
0.0011 | 17 (8.6%) |
11 ¶ (5.6%) |
NA | NA |
Age, sex, race, body mass index, and comorbidities (hypertension, chronic lower lung disease, diabetes mellitus, ischemic heart disease, chronic kidney disease, heart failure, cerebrovascular disease, nicotine dependence, and alcohol-related disorders) were included as covariates in propensity score matching. DMARDs disease-modifying antirheumatic drugs, ICU Intensive care unit, KRT Kidney replacement therapy, ARDS Acute respiratory distress syndrome, VTE Venous thromboembolism, NA Not applicable.
TriNetX obfuscates the number if it is less than 11 due to privacy reasons.
† Tumor necrosis factor inhibitors inhibitors included adalimumab, etanercept, infliximab, golimumab, certolizumab,.
§ Composite of mechanical ventilation and mortality.